ICMR Develops Novel Dual-Stage Malaria Vaccine Candidate

In July 2025, the Indian Council of Medical Research (ICMR) announced that it is developing a next-generation malaria vaccine, AdFalciVax, in collaboration with multiple national research institutions. This innovative vaccine targets multiple stages of the Plasmodium falciparum parasite, the deadliest malaria strain.

Key Points

Collaborating Institutions: The vaccine is being developed by ICMR along with RMRC Bhubaneswar, NIMR, and DBT’s National Institute of Immunology.
Multistage Protection: AdFalciVax is a recombinant chimeric vaccine targeting both pre-erythrocytic and sexual stages of P. falciparum, offering individual protection and helping reduce mosquito-based transmission.
Unique Production Method: The vaccine is produced using Lactococcus lactis, a safe, food-grade bacterium.
Thermal Stability: It remains stable and functional for over nine months at room temperature, an important feature for tropical regions.
Preclinical Success: Early studies show broader protection, reduced immune evasion, and potential long-term immunity.
Technology Licensing: ICMR plans to license AdFalciVax to eligible partners under non-exclusive terms, aligned with its IP policy.
Make in India Aligned: The vaccine supports India’s malaria elimination strategy and is being developed under the Make in India initiative.
Not Yet Approved: The vaccine is currently in early development and not approved for clinical use.